Megakaryocyte and platelet inhibitory receptor G6b (MPIG6B, also known as C6orf25) is a critical immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor. Primarily expressed on the lineage of megakaryocytes and platelets, MPIG6B acts as a master regulator of platelet production and activation. It represents a highly specialized therapeutic target for thrombocytopenia, myelofibrosis, myeloproliferative neoplasms (MPNs), and abnormal megakaryopoiesis.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MPIG6B (C6orf25) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MPIG6B ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View MPIG6B Products |
| Gene Delivery | MPIG6B Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Conformationally intact expression. |
View MPIG6B Products |
| Benchmark Ab | Anti-MPIG6B Recombinant Antibody Recombinant positive control derived from clinical-grade reference sequences. |
View MPIG6B Products |
| Validator | MPIG6B siRNA Set For target knockdown verification in megakaryocytic cell lines (e.g., K562, MEG-01). |
View MPIG6B Products |
| Related Target A | GPVI (Glycoprotein VI) Collagen receptor working in functional opposition to MPIG6B in platelet activation pathways. |
View GPVI Products |
| Related Target B | MPL (Thrombopoietin Receptor) Core driver of megakaryopoiesis, showing synergistic signaling crosstalk with MPIG6B. |
View MPL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heparin/Heparan Sulfate binding interference | HEK293-expressed MPIG6B with native post-translational modifications, ensuring physiological glycan-mediated ligand binding. |
| Species cross-reactivity (Human vs. Mouse) | Sequence-verified human and mouse MPIG6B ortholog proteins available with >95% purity for robust pre-clinical screening. |
| Lack of Controls | Sequence-authenticated clinical benchmark antibodies included as functional assay controls. |
| False Positives in Knockdown assays | Validated siRNA pools targeting multiple MPIG6B exons to confirm phenotypic specificity. |
Live MPIG6B (C6orf25) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MPIG6B (C6orf25) is an emerging frontier in hematological medicine. Historically viewed as an orphan platelet receptor, recent genetic and functional validation has positioned MPIG6B as a key gatekeeper of megakaryocyte maturation and myelofibrosis progression. The race for MPIG6B therapeutics is intensifying, with major players shifting focus from traditional small molecules to agonist monoclonal antibodies and bispecific formats. As first-generation therapies reach pre-clinical and early clinical validation, the next wave of R&D is targeting the modulation of MPIG6B interaction with its physiological ligands (such as heparin and heparan sulfate proteoglycans) to treat severe thrombocytopenia and bone marrow fibrosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist Antibody | Academic Institutes / Biotech | Myelofibrosis, Essential Thrombocythemia | Receptor oligomerization & phosphorylation assays (Requires high-purity ECD-Fc) |
| Antagonist Antibody | Biotech / Hematology Specialists | Thrombocytopenia, Platelet Dysfunction | Ligand-blocking assays (Requires native-glycosylated MPIG6B protein) |
| Bispecific / Multispecific | Translational Research Hubs | Megakaryoblastic Leukemia | Co-engagement verification (Requires multi-species ortholog panels) |